Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by Alberto Zangrillo and Corrado Campochiaro.
Alberto Zangrillo
Connection Strength
0.789
Corrado Campochiaro
  1. Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-centre retrospective cohort study. Eur J Intern Med. 2020 06; 76:43-49.
    View in: PubMed
    Score: 0.221
  2. Immunosuppressive strategies in invasively ventilated ARDS COVID-19 patients. Minerva Anestesiol. 2021 08; 87(8):891-902.
    View in: PubMed
    Score: 0.059
  3. Respiratory Impairment Predicts Response to IL-1 and IL-6 Blockade in COVID-19 Patients With Severe Pneumonia and Hyper-Inflammation. Front Immunol. 2021; 12:675678.
    View in: PubMed
    Score: 0.059
  4. Pneumothorax/pneumomediastinum in non-intubated COVID-19 patients: Differences between first and second Italian pandemic wave. Eur J Intern Med. 2021 06; 88:144-146.
    View in: PubMed
    Score: 0.058
  5. Interleukin-1 and interleukin-6 inhibition compared with standard management in patients with COVID-19 and hyperinflammation: a cohort study. Lancet Rheumatol. 2021 Apr; 3(4):e253-e261.
    View in: PubMed
    Score: 0.058
  6. Targeting IL-1, IL-6 or GM-CSF in COVID-19. Response to: 'More evidences on which biologic and which pathway is key in severe-critical COVID-19 pneumonia' by Ferraccioli. Ann Rheum Dis. 2020 Jul 31.
    View in: PubMed
    Score: 0.056
  7. Prevalence, Characteristics, Risk Factors, and Outcomes of Invasively Ventilated COVID-19 Patients with Acute Kidney Injury and Renal Replacement Therapy. Blood Purif. 2021; 50(1):102-109.
    View in: PubMed
    Score: 0.056
  8. Low prevalence of arrhythmias in clinically stable COVID-19 patients. Pacing Clin Electrophysiol. 2020 08; 43(8):891-893.
    View in: PubMed
    Score: 0.056
  9. Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation: an open-label cohort study. Ann Rheum Dis. 2020 10; 79(10):1277-1285.
    View in: PubMed
    Score: 0.056
  10. GM-CSF blockade with mavrilimumab in severe COVID-19 pneumonia and systemic hyperinflammation: a single-centre, prospective cohort study. Lancet Rheumatol. 2020 Aug; 2(8):e465-e473.
    View in: PubMed
    Score: 0.055
  11. Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study. Lancet Rheumatol. 2020 Jun; 2(6):e325-e331.
    View in: PubMed
    Score: 0.055
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.